Diversity Considerations in HIV-1 Vaccine Selection

Globally, human immunodeficiency virus-type 1 (HIV-1) is extraordinarily variable, and this diversity poses a major obstacle to AIDS vaccine development. Currently, candidate vaccines are derived from isolates, with the hope that they will be sufficiently cross-reactive to protect against circulatin...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2002-06, Vol.296 (5577), p.2354-2360
Main Authors: Gaschen, Brian, Taylor, Jesse, Yusim, Karina, Foley, Brian, Gao, Feng, Lang, Dorothy, Novitsky, Vladimir, Haynes, Barton, Hahn, Beatrice H., Bhattacharya, Tanmoy, Korber, Bette
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Globally, human immunodeficiency virus-type 1 (HIV-1) is extraordinarily variable, and this diversity poses a major obstacle to AIDS vaccine development. Currently, candidate vaccines are derived from isolates, with the hope that they will be sufficiently cross-reactive to protect against circulating viruses. This may be overly optimistic, however, given that HIV-1 envelope proteins can differ in more than 30% of their amino acids. To contend with the diversity, country-specific vaccines are being considered, but evolutionary relationships may be more useful than regional considerations. Consensus or ancestor sequences could be used in vaccine design to minimize the genetic differences between vaccine strains and contemporary isolates, effectively reducing the extent of diversity by half.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.1070441